IP Library Granted Patent US 12,448,359
Granted Patent B2
US 12,448,359 · App. 17/908,530 · Granted Oct 21, 2025

Compounds with immunomodulatory activity and therapeutic uses thereof

Inventors: Gaurav Chopra (West Lafayette, IN); Prageeth Wijewardhane (West Lafayette, IN); Krupal P. Jethava (West Lafayette, IN); Jonathan Fine (Jersey City, NJ)
Assignee: Purdue Research Foundation
C07D277/24C07D211/32C07D319/20C07D413/06C07D413/14C07D419/04C07D419/14C07F5/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,448,359
App. No.
17/908,530
Granted
Oct 21, 2025
Kind
B2
Abstract

The present invention generally relates to new compounds for therapeutic uses. In particular, the disclosed series compounds with immunomodulatory activities are useful for treatment of dysfunctions of the immune system and various cancers. Pharmaceutical composition matters and methods for treating a patient with an immune disease and/or a cancer by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.

Claims (12)

1. A compound having the formula (I):

or a pharmaceutically acceptable salt thereof, wherein

Ar 1 is 2,3-dihydrobenzo [b] [1,4]-dioxinyl;

R 1 and R 2 are each, independently, alkyloxy;

R 3 is alkyl; and

Q is

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are each methoxyl.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is CH 3 .

4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:

5. A pharmaceutical composition comprising one or more compounds of claim 1 , or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.

6. A method for treating a cancer patient, which method comprises administering a therapeutically effective amount of one or more compounds of claim 1 , or a pharmaceutical composition comprising same and one or more carriers, diluents, or excipients, to the cancer patient.

7. The method according to claim 6 , wherein said cancer is castration-resistant prostate cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2022
From: CHOPRA, GAURAV; FINE, JONATHAN; JETHAVA, KRUPAL P.; WIJEWARDHANE, PRAGEETH
To: PURDUE RESEARCH FOUNDATION
Reel/Frame 061367/0221 →
Continuity (2)
Provisional Application 62987914 · Mar 11, 2020
Related Publication 20230159475A1 · May 25, 2023
References Cited (19)
US 10493078B2 · Chu et al. · 2019 [cited by applicant]
US 20150291549A1 · Chupak · 2015 [cited by examiner]
US 20160194307A1 · Chupak et al. · 2016 [cited by applicant]
US 20190016661A1 · Inoue et al. · 2019 [cited by applicant]
US 20190016681A1 · Dömling · 2019 [cited by applicant]
CA 3175848 · 2021 [cited by applicant]
CN 105705489 · 2016 [cited by applicant]
WO WO2015034820A1 · 2015 [cited by examiner]
WO 2015160641 · 2015 [cited by applicant]
WO 2019197903 · 2019 [cited by applicant]
WO 2021183370 · 2021 [cited by applicant]
“Chinese Application Serial No. 202180033571.3, Office Action mailed Dec. 7, 2023”, w English translation, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-554529, Voluntary Amendment filed Mar. 1, 2024”, 25 pgs. [cited by applicant]
“European Application Serial No. 21767165.0, Partial Supplementary European Search Report mailed Apr. 30, 2024”, 19 pgs. [cited by applicant]
“International Application Serial No. PCT US2021 020992, International Preliminary Report on Patentability mailed Sep. 22, 2022”, 9 pgs. [cited by applicant]
“Chinese Application Serial No. 202180033571.3, Response filed Jun. 14, 2024 to Office Action mailed Dec. 7, 2023”, w English claims, 18 pgs. [cited by applicant]
International Search Report and Written Opinion, issued by the ISA/US, Commissioner for Patents, for International Application No. PCT/US2021/020992, mailed Jul. 20, 2021. [cited by applicant]
Abdel-Magid, A. F., Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections, ACS Medical Chemistry Letters, 2015, 6, pp. 489-490. [cited by applicant]
Flynn, G. L. et al., Correlation and Prediction of Mass Transport Across Membranes I: Influence of Alkyl Chain Length on Flux-Determining Properties of Barrier and Diffusant, Journal of Pharmaceutical Sciences, Jun. 197… [cited by applicant]